Glaucoma News and Research

Latest Glaucoma News and Research

Alcon second-quarter adjusted EPS increases 14.4% to $2.22 per share

The Alcon Independent Director Committee noted today that Alcon once again delivered strong earnings in the second quarter of 2010. Alcon's 2Q 2010 Adjusted EPS of $2.22 per share represented a year-over-year growth rate of 14.4% and exceeded Wall Street's mean consensus estimate of $2.03 per share by 9.4%. Alcon's strong EPS growth was driven by an 11.3% increase in organic sales resulting, in part, from a 22.3% increase in advanced technology intraocular lens sales, a 17.2% increase in glaucoma sales and a 24.2% increase in emerging market sales.

27 Jul 2010

Alcon second-quarter global sales increase 12.5% to $1.89 billion

Alcon, Inc. reported that global sales rose 12.5 percent to $1.89 billion for the second quarter of 2010, or 11.3 percent excluding the impact of foreign exchange fluctuations and acquisitions. Revenue from acquisitions added 40 basis points to sales growth in the quarter, while foreign currency fluctuations added 80 basis points of growth.

27 Jul 2010

Somaxon's Silenor Phase 3 clinical data accepted for publication in Sleep, Sleep Medicine journals

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that detailed results from two Phase 3 clinical trials of the company's product Silenor® (doxepin) have been accepted for publication in peer-reviewed scientific journals.

22 Jul 2010

AHAF enters new partnership with BioMed Central's Molecular Neurodegeneration journal

The American Health Assistance Foundation (AHAF) today announced a new partnership with BioMed Central's open access journal, Molecular Neurodegeneration (MN) in which the publication will be the official open access journal of AHAF.

21 Jul 2010

ARUP enters partnership to offer deCODE's DNA-based prostate cancer risk assessment test

deCODE genetics and ARUP Laboratories today announced a partnership through which ARUP will offer deCODE's DNA-based prostate cancer risk assessment test to its clients nationwide.

20 Jul 2010

New myopia control technology for eye health benefits from Vision CRC

Scientists from the Vision Cooperative Research Centre in Australia have announced that myopia, or short-sightedness, can be controlled with new technology. This ground breaking discovery was based on research conducted by Vision CRC partners – the University of Houston College of Optometry and the Brien Holden Vision Institute, located at the University of New South Wales.

15 Jul 2010

Phase 1/2 clinical study of bepotastine besilate nasal spray initiated for seasonal allergic rhinitis

ISTA Pharmaceuticals, Inc., today announced it has initiated a Phase 1/2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group study will evaluate the safety and efficacy of three concentrations of bepotastine besilate, dosed twice daily, in an Environmental Exposure Chamber model of allergic rhinitis caused by natural exposure to seasonal allergens.

14 Jul 2010

Common SNP in sequence of human genome conferring risk of vascular diseases discovered

Scientists at deCODE genetics and academic colleagues from the Netherlands and twelve other countries across Europe and North America today report the discovery of a common single-letter variation (SNP) in the sequence of the human genome conferring risk of a range of vascular diseases. The SNP confers risk of abdominal aortic aneurysm (AAA), early-onset heart attack, peripheral artery disease (PAD), and pulmonary embolism, independent of other known risk factors.

12 Jul 2010

Shire receives FDA approval of Daytrana for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

7 Jul 2010

Phase Ia clinical trial of SYL040012 for treating elevated intraocular pressure, glaucoma completed

Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has completed Phase Ia of its first clinical trial with SYL040012 in the form of ophthalmic drops to treat elevated intraocular pressure and glaucoma.

7 Jul 2010

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Fera Pharmaceuticals is pleased to announce the launch of Neptazane (Methazolamide) 25 mg and 50 mg tablets. Both strengths are available in 90 count bottles.

3 Jul 2010

Research findings suggest new treatment approach to improve corneal transplants

Although it is already one of medicine's most successful transplant procedures, doctors continue to seek ways to improve corneal transplants. Now, for the first time, a team of German and British researchers have confirmed that failure and rejection of transplanted corneas are more likely in patients whose eyes exhibit abnormal vessel growth, called corneal neovascularization, prior to surgery.

1 Jul 2010

AqueSys secures $35 million in Series C financing round

AqueSys, Inc., a medical device company that develops, manufactures and distributes proprietary implants for glaucoma, today announced that it has secured $35 million in Series C financing. The round was led by Longitude Capital and Rho Ventures, with participation from existing investors Accuitive Medical Ventures, The Carlyle Group and SV Life Sciences.

30 Jun 2010

Quark reports results from QPI-1007 siRNA drug study in rat ocular hypertension model of glaucoma

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced results from a second study of QPI-1007, a neuroprotective siRNA drug, in rat ocular hypertension model of glaucoma, conducted by Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal.

29 Jun 2010

Sunridge International delivers 60 PNT Units and 10,000 disposable rings to BV of China

Sunridge International, announced today that it has completed production and delivery of 60 PNT Units and 10,000 disposable rings to its exclusive distributor, Beijing Vision World Trading Company (BV) of China.

28 Jun 2010

Quark Pharmaceuticals' siRNA drug candidates featured in two presentations at Glaucoma & Retinopathies 2010

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that two of its siRNA drug candidates were featured in the following two presentations at the Glaucoma & Retinopathies 2010 conference, which was held June 21-22, 2010 in London, UK.

25 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Debiotech, STMicroelectronics to showcase novel insulin "Jewel Pump" at ADA Congress

Debiotech and STMicroelectronics today announced that they will publicly showcase their novel insulin "Jewel Pump" at the Debiotech stand at the American Diabetes Association 70th Scientific Sessions (June 25-29) in Orlando, Florida.

24 Jun 2010

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.

22 Jun 2010

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

17 Jun 2010

Glaucoma News and Research

Latest Glaucoma News and Research

Alcon second-quarter adjusted EPS increases 14.4% to $2.22 per share

Alcon second-quarter global sales increase 12.5% to $1.89 billion

Somaxon's Silenor Phase 3 clinical data accepted for publication in Sleep, Sleep Medicine journals

AHAF enters new partnership with BioMed Central's Molecular Neurodegeneration journal

ARUP enters partnership to offer deCODE's DNA-based prostate cancer risk assessment test

New myopia control technology for eye health benefits from Vision CRC

Phase 1/2 clinical study of bepotastine besilate nasal spray initiated for seasonal allergic rhinitis

Common SNP in sequence of human genome conferring risk of vascular diseases discovered

Shire receives FDA approval of Daytrana for ADHD in adolescents

Phase Ia clinical trial of SYL040012 for treating elevated intraocular pressure, glaucoma completed

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Research findings suggest new treatment approach to improve corneal transplants

AqueSys secures $35 million in Series C financing round

Quark reports results from QPI-1007 siRNA drug study in rat ocular hypertension model of glaucoma

Sunridge International delivers 60 PNT Units and 10,000 disposable rings to BV of China

Quark Pharmaceuticals' siRNA drug candidates featured in two presentations at Glaucoma & Retinopathies 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Debiotech, STMicroelectronics to showcase novel insulin "Jewel Pump" at ADA Congress

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Glaucoma News and Research

Latest Glaucoma News and Research

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Newsletters you may be interested in